Loading
Arvinas, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 09 Mar 2026.
Arvinas, Inc.: what insiders have been doing
This page follows insider dealings at Arvinas, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. 16 insiders have disclosed 35 filings since 18 October 2025.
Purchases and sales both appear in the filings: 1 purchase (1 insider, €231k) and 15 sales (6 insiders, €391k). The totals do not cover 2 filings with an undisclosed amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Morrison Briggs filed the largest purchase, €231k, on 9 March 2026. Among those who bought: 1 senior executive.
The last insider purchase was made public on 9 March 2026, 223 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Across the 5,811 companies tracked on its exchange, the median is 19 filings; at 35 filings, this issuer sits above that mark. Our records for Arvinas, Inc. go back to 2021, with 2 purchases and 40 sales on the open market in total. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 262.6 m USD and net income at -80.8 m USD.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
136
Thresholds
n/a
Buy Volume
€423,298
2 ops. · all time
Sell Volume
€17M
40 ops. · all time
Who traded when
BuySaleAngela M. Cacace6 sales
David K. Loomis6 sales
Andrew Saik3 sales
Houston John G3 sales
Noah Berkowitz3 sales
Randy Teel3 sales
+2 other insiders
Since the insiders bought
- -48.3%Entry US$13.83 · Close at T+90 US$7.15
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Arvinas, Inc. Buy (bullish), based on 14 analysts. Average price target: US$13.93.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 23,364 of 24,148 companies
12.9
score / 100
Value7
Quality19
FCF yld-60%
Earn yld-18%
EV/EBITDA·
ROE1.6%
Gross mgn·
Net mgn-31%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$6.82
Analyst consensus
14 analystsBuy
US$6.00Target US$13.93(+104%)US$21.00
Income statement
RevenueUS$262.6M
EBITDA-US$113.3M-43% margin
Net income-US$80.8M2.9% margin
Valuation
PER (trailing)26.2x
PER (forward)-2.1x
P/Book0.8x
Beta1.81
Balance sheet & cash
Market capUS$445.9M
Total debtUS$8.9M
Free Cash Flow-US$275.7M
Debt / Equity1%
Profitability & ownership
ROE1.6%
ROA-1.0%
% insiders7.8%
% institutions84.0%
Last declaration on 22 September 2026
Declarations136 total
23,105 shares@ US$8.49350.039% mcap100.0% of flowCommonSEC144:0001950047-26-009754
37,200 shares@ US$8.84180.065% mcap37.4% of flowCommonSEC144:0001950047-26-009237
8,300 shares@ US$9.45040.015% mcap8.9% of flowCommonSEC144:0001950047-26-009128
30,000 shares@ US$8.800.053% mcap30.3% of flowCommonSEC144:0001950047-26-007606
24,000 shares@ US$8.3970.040% mcap23.3% of flowCommonSEC144:0001950047-26-006977
15,527 sharesCommon StockSEC:0001628280-26-045783:0
15,527 sharesCommon StockSEC:0001628280-26-045785:0
15,527 sharesCommon StockSEC:0001628280-26-045786:0
15,527 sharesCommon StockSEC:0001628280-26-045787:0
15,527 sharesCommon StockSEC:0001628280-26-045788:0
15,527 sharesCommon StockSEC:0001628280-26-045781:0
5,696 sharesCommon StockSEC:0001628280-26-045286:0
5,846 shares@ US$8.14100.0% of flowCommonSEC144:0001628280-26-044980
2,576 sharesCommon StockSEC:0001628280-26-044270:0
2,642 shares@ US$7.42100.0% of flowCommonSEC144:0001628280-26-043732
2,209 shares@ US$9.03650.0034% mcap23.9% of flowCommon StockSEC:0001628280-26-037728:0
1,919 shares@ US$9.93740.0032% mcap24.9% of flowCommon StockSEC:0001628280-26-034612:0
6,435 shares@ US$11.100433.1% of flowCommon StockSEC:0001628280-26-019950:0
147,179 shares0Common StockSEC:0001628280-26-017385:0
20,000 shares@ US$13.403526.0% of flowCommon StockSEC:0001628280-26-016003:0
Canonical exit: 4 Jun 2026 (T+90)
12,420 shares0Common StockSEC:0001628280-26-013537:0
147,791 shares0Common StockSEC:0001628280-26-013529:0
45,000 shares0Common StockSEC:0001628280-26-013531:0
45,000 shares0Common StockSEC:0001628280-26-013535:0
45,000 shares0Common StockSEC:0001628280-26-013533:0
25 of 136 declarations
About Arvinas, Inc.
Arvinas, Inc. is a United States-based biopharmaceutical company listed on the NASDAQ under the ticker ARVN, with its headquarters in New Haven, Connecticut, United States. Founded in 2013, the company was built around a proprietary targeted protein degradation platform and is widely associated with PROTACs, or proteolysis targeting chimeras. Rather than merely inhibiting disease-driving proteins, Arvinas aims to eliminate them by leveraging the cell’s natural protein disposal machinery. This positions the company in one of the most innovative areas of modern drug discovery, spanning oncology and neurodegenerative disease.
Arvinas is best described as a clinical-stage biotechnology company. It remains pre-commercial, with value creation driven primarily by research and development, clinical execution, and partnership economics rather than product sales. Its platform is designed to address high-value targets, including proteins historically considered difficult or impossible to drug with conventional small molecules. The company’s most visible programs include ARV-102, ARV-806, ARV-393, ARV-027, and ARV-6723, reflecting a pipeline that spans both oncology and neuroscience. Arvinas has also worked with major pharmaceutical partners, a model that can help defray development costs while broadening the long-term commercial opportunity for its technology.
Read moreShow less
From a competitive standpoint, Arvinas holds a meaningful position in the emerging targeted protein degradation field. Its differentiation lies in the depth of its discovery engine, the scientific credibility of its platform, and its relative clinical lead in certain assets. The company has also highlighted that it has advanced at least one investigational drug through a pivotal trial and regulatory submission in the United States, which is an important validation point for a company still in the development stage.
Geographically, Arvinas is primarily rooted in the United States, with operations centered in New Haven. That said, its platform and collaborations give it potential reach well beyond the domestic market, including Europe and other regions through licensing and partnership structures. For investors, the key takeaway is that Arvinas is a high-risk, high-upside biotechnology story whose valuation is likely to be driven by clinical readouts, regulatory milestones, partner activity, and capital allocation discipline.
A recent highlight came in February 2026, when Arvinas reported fourth-quarter and full-year 2025 results and said it expected cash runway into the second half of 2028. Management also pointed to multiple potential value-driving milestones in 2026 across ARV-102, ARV-806, ARV-393, ARV-027, and ARV-6723. In addition, the company announced the appointment of Randy Teel, Ph.D., as President, CEO, and director. Separately, SEC Form 4 filings indicate continuing insider transaction activity, which market participants often watch closely in a company of this profile.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
